Immunology/Inflammation
Read More about this categoryShow Less
The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.
Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].
BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].
Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.
Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].
References
[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.
[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.
[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.
[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.
[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.
[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.
[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.
[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.
Research Areas
- 5-Lipoxygenase(17)
- Apoptosis(675)
- Cyclic GMP-AMP Synthase(6)
- TLR(121)
- Papain(1)
- PGDS(1)
- PGE synthase(26)
- SIKs(12)
- IκB/IKK(68)
- AP-1(11)
- KEAP1-Nrf2(56)
- NOD1(1)
- NF-κB(304)
- Interleukin Related(263)
- 15-lipoxygenase(2)
- Others(10)
- Aryl Hydrocarbon Receptor(40)
- CD73(15)
- Complement System(69)
- Galectin(12)
- IFNAR(54)
- NO Synthase(93)
- NOD-like Receptor (NLR)(66)
- STING(118)
- Reactive Oxygen Species(505)
- FKBP(15)
- eNOS(4)
- iNOS(29)
- nNOS(20)
- Glutathione(54)
- Adaptive Immunity(210)
- Allergy(118)
- Arthritis(34)
- Autoimmunity(181)
- Gastric Disease(94)
- Immunosuppressants(38)
- Immunotherapeutics(4)
- Innate Immunity(566)
- Pulmonary Diseases(109)
- Reactive Nitrogen Species(50)
- Specialized Pro-Resolving Mediators(49)
- Reactive Sulfur Species(28)
- BCL6(5)
- CD20(10)
- CD28(3)
- PSMA(12)
- FAP(16)
- Nuclear Factor of activated T Cells (NFAT)(2)
- Glycoprotein VI(2)
- Tim3(3)
- Hapten(1)
- Nectin-4(2)
- DOCK(1)
- MHC(9)
- Transmembrane Glycoprotein(17)
- TREM receptor(9)
- Inflammation or Immune System Disease(2)
- Musculoskeletal and Skin Disease(1)
- Fc Receptor (FcR)(11)
- IKZF Family(4)
- C-type Lectin-like Receptors (CTLRs)(3)
- Asialoglycoprotein Receptor (ASGPR)(3)
- Human leukocyte immunoglobulin (Ig)-like receptors (LILR)(1)
Products Related to Immunology/Inflammation(4435)
- GC90702Triciribine PhosphateCAS: 61966-08-3Purity: >95.00%
Un inhibidor de la activación de Akt y metabolito activo de triciribina.
- GC907441,2-Dioleoyl-3(R)-trimethylammoniumpropane (chloride)CAS: 328250-28-8Purity: >95.00%
Un lípido catiónico
- GC907741-Linoleoyl Lysophosphatidic Acid (sodium salt)CAS: 72777-86-7Purity: >95.00%
Un glicerofosfolípido
- GC90781Ambroxol-d5 (hydrochloride)CAS: 2741380-71-0Purity: >99.00%
Un estándar interno para la cuantificación de ambroxol.
- GC90794Adenosine 5'-methylenediphosphate (sodium salt)CAS: 2659222-76-9Purity: >98.00%
Un inhibidor de la ecto-5'-nucleotidasa.
- GC908032',3'-Dideoxyadenosine-5'-O-triphosphate (sodium salt)CAS: 99827-72-2Purity: >95.00%
Un inhibidor de la transcriptasa inversa y un metabolito activo de ddA y ddI.
- GC908111-Palmitoyl-d9-2-Arachidonoyl-sn-glycero-3-PCCAS: 1872379-11-7Purity: >99.00%
Un estándar interno para la cuantificación de 1-palmitoil-2-arachidonoil-sn-glicero-3-PC.
- GC908235-(3-Aminoallyl)uridine-5'-O-triphosphate (sodium salt)CAS: 85280-66-6Purity: >95.00%
Un nucleótido modificado con amina.
- GC908678-bromo NAD+ (sodium salt)CAS: 2022926-16-3Purity: >95.00%
Una forma de profármaco de 8-bromo-cADPR.
- GC90883Purine riboside-5'-O-triphosphate (sodium salt)CAS: 35892-95-6Purity: >95.00%
Un metabolito activo de la nebularina.
- GC908895-(3'-Hydroxyphenyl)-γ-ValerolactoneCAS: 21618-91-7Purity: >95.00%
Un metabolito de varios polifenoles.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC90701 | CAY10795 | 2241676-74-2 | >98.00% | |
Un inhibidor de 15-PGDH | ||||
| GC90702 | Triciribine Phosphate | 61966-08-3 | >95.00% | |
Un inhibidor de la activación de Akt y metabolito activo de triciribina. | ||||
| GC90703 | IC8 | 2349307-32-8 | >95.00% | |
Un lípido catiónico ionizable. | ||||
| GC90704 | Sphinganine (d17:0) (hydrochloride) | - | >95.00% | |
Un esfingolípido bioactivo sintético | ||||
| GC90705 | BSP-16 | 2727249-47-8 | >98.00% | |
Un agonista de STING | ||||
| GC90710 | CAY10723 (hydrochloride) | - | >95.00% | |
Un inhibidor de PAD2 | ||||
| GC90744 | 1,2-Dioleoyl-3(R)-trimethylammoniumpropane (chloride) | 328250-28-8 | >95.00% | |
Un lípido catiónico | ||||
| GC90750 | cKK-E15 | 1432494-71-7 | >95.00% | |
Un lípido catiónico ionizable. | ||||
| GC90772 | YK-009 | 2761458-86-8 | >95.00% | |
Un lípido catiónico ionizable. | ||||
| GC90774 | 1-Linoleoyl Lysophosphatidic Acid (sodium salt) | 72777-86-7 | >95.00% | |
Un glicerofosfolípido | ||||
| GC90781 | Ambroxol-d5 (hydrochloride) | 2741380-71-0 | >99.00% | |
Un estándar interno para la cuantificación de ambroxol. | ||||
| GC90784 | STING Agonist 12L | 2913152-30-2 | >98.00% | |
Un agonista de STING | ||||
| GC90785 | STING Agonist 23 | 2951078-67-2 | >99.50% | |
Un agonista de STING | ||||
| GC90794 | Adenosine 5'-methylenediphosphate (sodium salt) | 2659222-76-9 | >98.00% | |
Un inhibidor de la ecto-5'-nucleotidasa. | ||||
| GC90803 | 2',3'-Dideoxyadenosine-5'-O-triphosphate (sodium salt) | 99827-72-2 | >95.00% | |
Un inhibidor de la transcriptasa inversa y un metabolito activo de ddA y ddI. | ||||
| GC90811 | 1-Palmitoyl-d9-2-Arachidonoyl-sn-glycero-3-PC | 1872379-11-7 | >99.00% | |
Un estándar interno para la cuantificación de 1-palmitoil-2-arachidonoil-sn-glicero-3-PC. | ||||
| GC90813 | 2'-deoxy NAD+ (sodium salt) | 1514900-83-4 | >95.00% | |
Un agonista de TRPM2 | ||||
| GC90823 | 5-(3-Aminoallyl)uridine-5'-O-triphosphate (sodium salt) | 85280-66-6 | >95.00% | |
Un nucleótido modificado con amina. | ||||
| GC90867 | 8-bromo NAD+ (sodium salt) | 2022926-16-3 | >95.00% | |
Una forma de profármaco de 8-bromo-cADPR. | ||||
| GC90883 | Purine riboside-5'-O-triphosphate (sodium salt) | 35892-95-6 | >95.00% | |
Un metabolito activo de la nebularina. | ||||
| GC90886 | SZM-1209 | 2919801-86-6 | >98.00% | |
Un inhibidor de RIPK1 | ||||
| GC90889 | 5-(3'-Hydroxyphenyl)-γ-Valerolactone | 21618-91-7 | >95.00% | |
Un metabolito de varios polifenoles. | ||||
| GC90912 | DNCA | 2226561-66-4 | >95.00% | |
Un lípido neutro | ||||
| GC90924 | TNP-GTP (sodium salt) | - | >95.00% | |
Un derivado fluorescente de GTP | ||||
